Oruka Therapeutics CEO Sells Shares as Analysts Remain Bullish
CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics, valued at $120,494.01.
Key Points
- Oruka Therapeutics CEO Lawrence Otto Klein sold 1,729 shares valued at $120,494.01 on June 15, 2026.
- Shares of NasdaqGM:ORKA trade near $69.89 with a market cap of $4.22 billion and a 52-week high of $91.00.
- Analysts maintain a strong buy consensus with a target mean price of $142.17 across 12 opinions.
On June 15, 2026, Lawrence Otto Klein, the CEO of Oruka Therapeutics, Inc. (NasdaqGM:ORKA), sold 1,729 shares of the company. This transaction, not part of a pre-arranged trading plan, was valued at approximately $120,494.01.
Insider Buying and Selling at Oruka Therapeutics, Inc.
In addition to CEO Lawrence Otto Klein's sale, other insiders also made transactions on June 15. Joana Goncalves, the Chief Medical Officer, bought 7,000 shares at $7.32 each and sold 3,500 shares at an undisclosed price. Laura Lee Sandler, the Chief Operating Officer, sold 600 shares at $69.69 each. Arjun Agarwal, Senior Vice President of Finance, sold 395 shares under a pre-arranged plan, while Paul Quinlan, General Counsel, sold 733 shares at $69.69.
Other Institutional Activity in Oruka Therapeutics
Institutional investors have been active in Oruka Therapeutics. FMR LLC increased its holdings by 170,019 shares, bringing its total to 7,431,403 shares, worth about $364.51 million. BlackRock, Inc. slightly reduced its position by 12,328 shares, ending with 3,527,087 shares valued at $173.00 million. Paradigm Biocapital Advisors LP significantly boosted its stake by 610,000 shares, totaling 2,320,316 shares worth approximately $113.81 million.
Oruka Therapeutics Stock Snapshot
Shares of Oruka Therapeutics are trading near $69.89. The company has a market capitalization of $4.22 billion. While it has no meaningful P/E ratio due to ongoing losses, its forward P/E is -28.39, reflecting negative earnings. The stock's 52-week range is between $10.77 and $91.00, with a 50-day moving average of $63.70 and a 200-day moving average of $37.60. The company shows strong liquidity with a current ratio of 23.76 and a quick ratio of 23.38, alongside a low debt-to-equity ratio of 0.37.
Analysts Set New Price Targets
Analysts remain optimistic about Oruka Therapeutics. On May 14, 2026, BTIG reiterated a buy rating with a price target of $151. HC Wainwright & Co. and UBS also maintained buy ratings with targets of $120 and $100, respectively, in late April. Overall, the consensus remains a strong buy, with a target mean price of $142.17 based on 12 analyst opinions.
About Oruka Therapeutics
Oruka Therapeutics, Inc., based in Menlo Park, California, is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for inflammatory and immunology conditions like psoriasis. The company is spearheaded by CEO Dr. Lawrence Otto Klein and employs 68 people. Its leading products are in various stages of clinical trials, targeting interleukin pathways for conditions such as psoriatic arthritis.
Bottom Line
The recent insider sale by Oruka Therapeutics' CEO is notable but not necessarily indicative of the company's outlook. Institutional investors continue to adjust their positions, and analysts maintain a strong buy consensus, suggesting confidence in the company's future. As always, remember that insider trades and analyst ratings are just pieces of a larger investment puzzle.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.